GTx "buy," target price raised

12/06/06 - A.G. Edwards & Sons

NEW YORK, December 6 (newratings.com) - Analyst Aaron S Reames of AG Edwards reiterates his "buy" rating on GTx Inc (GTXI). The price objective has been raised from $16 to $23.

In a research note published this morning, the analyst mentions that the company is likely to release positive Phase II ostarine data in the forthcoming few weeks. GTx’s partner, Ipsen, is expected to file for the EU approval for Acapodene, alongside the drug’s US filing, the analyst says.